Medtronic, IBM launch diabetes management app

Medtronic and IBM Watson Health have announced the launch of an artificial intelligence (AI)-powered diabetes assistant application Sugar.IQ.

For the 30 million Americans diagnosed with diabetes, managing the chronic disease is an everyday task. With Sugar.IQ, patients can view patterns to make more informed decision on their care. Using AI and analytic technology, the app continually analyzes the user’s glucose levels when they eat and take insulin.

The personalized insights provided by the app show how lifestyle choices, medications and multiple daily injections impact diabetes management. By providing individual guidance, the app allows users to more informed decisions regarding daily management decisions.

In data presented at the 78th Annual American Diabetes Association (ADA) Scientific Sessions, researchers showed the app resulted in patients spending 36 more minutes in the healthy glucose range. Additionally, users spent 30 minutes less time in hyperglycemia and six minutes less time in hypoglycemia. This resulted in nine more days a year a patient spent in the healthy glucose range.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.